Bonaventura Clotet MD, PhD, is Head of the HIV Unit and director of the Retrovirology laboratory "irsiCaixa" Foundation at the Hospital Universitari "Germans Trias i Pujol", Badalona, Catalonia, Spain. Since February 2007 is also the co-director of the HIV research vaccine development in Catalonia. Dr. Clotet received his MD at the Universitat Autònoma de Barcelona in 1976 and his PhD in 1981 for his investigations on surrogate markers for connective tissue diseases. Dr. Clotet is part of the Drug Resistance Mutations Group of the International AIDS Society (IAS-USA) and he is also member of the Governing Council of the global IAS (International AIDS Society). He belongs to the board of different organizing committees of drug resistance workshops and international conferences on AIDS, and also an active member of the Expert Commission for the Evaluation of Research projects in the National Programme of Health and national AIDS Programme. He has published more than 500 papers in international journals and he is co-director of the AIDS CYBERJOURNAL and has been member of the editorial board of AIDS Journal for 8 years. He is currently reviewer of Lancet, JID, AIDS, CID, Antiviral Therapy, HIV Medicine, JAC and JAIDS. He has designed and coordinated several outstanding clinical studies such as the SWATCH, HAVANNA, RETROGEN, TIBET and INTENSE. Dr. Clotet has been co-chair of the Track B for the Barcelona World AIDS meeting 2002 and is Member of the Scientific Committee of the International Workshop on HIV drug Resistance and Treatment Strategies Meeting. He has authored numerous chapters in retrovirology, and he has been an invited speaker at numerous international and national conferences.